Clinical trials

At Octapharma, we are committed to better understanding von Willebrand disease and to improving the care of people with this condition.


Over 20 years of clinical and real-life experience have already proven the efficacy and tolerability of wilate® in people with all types of von Willebrand disease for surgery, prophylaxis and on-demand treatment.1-3 However, there is still more to learn. We continue to work with the scientific and clinical community to improve our understanding of von Willebrand disease, and are proud to support numerous clinical trials and investigator-initiated studies.

Published clinical trials with wilate®

in people with von Willebrand disease

Four prospective Phase II/III trials in 44 patients 3
Real-world Phase IV study in 111 patients 7
Phase III study in 12 children under 6 years of age (WIL-33) 9
Prospective Phase II trial in 15 children 4
Phase III study in 28 patients undergoing surgery 1
Phase III study of prophylaxis in 33 patients aged 6 or over (WIL-31) 8
1998
2002
2006
2010
2014
2018
2022
2026
Real-world study in 54 adults 5
Real-world study in 47 children6
Octapharma sponsored clinical study
Investigator-initiated study

Ongoing studies in  von Willebrand disease

As part of Octapharma’s long-standing commitment to addressing the unmet clinical needs of people with von Willebrand disease, Octapharma continues to carry out clinical trials to better understand the clinical efficacy and safety of wilate® in different patient populations

PopPK: Real-world study of pharmacokinetics-guided wilate ® prophylaxis in persons with severe von Willebrand disease
2020
2021
2022
2023
2024
2026
2028
Real-world study in 54 adults 5
EMPOWER study of wilate® prophylaxis in women with heavy menstrual bleeding
Octapharma sponsored clinical study
Investigator-initiated study
Link to the trials on clinicaltrials.gov
VIP-study or EMPOWER-study

Clinical studies

Octapharma sponsored clinical study
Octapharma sponsored clinical study
PopPK-WILPROPHY (WIL-36)

Real-world study of pharmacokinetics-guided wilate® prophylaxis in persons with severe von Willebrand disease

For more details, visit
Von Willebrand Factor in Pregnancy (VIP) Study

Real-world study of pharmacokinetics-guided wilate® prophylaxis in persons with severe von Willebrand disease

For more details, visit
vipstudy.com or clinicaltrials.gov
Principal Investigators
Jill M. Johnsen MD
Bloodworks, Seattle, WA, USA

 

Barbara A. Konkle MD
Bloodworks, Seattle, WA, USA

Peter A. Kouides, MD
Mary M. Gooley Hemophilia Center, Rochester, NY, USA
EMPOWER study of wilate® prophylaxis in 
women with heavy menstrual bleeding

A multi-cEntre Pilot Crossover Trial of Prophylactic wilate® coMpared to PlacebO for heavy menstrual bleeding in Patients with low von WillEbrand factoR and von Willebrand Disease (EMPOWER)

For more details, visit
clinicaltrials.gov
Principal Investigators
Michelle Sholzberg MDCM
University of Toronto​, Toronto, Canada

References

  1. Srivastava A et al. Haemophilia 2017; 23:264-72.
  2. Windyga J and von Depka-Prondzinski M. Thromb Haemost 2011; 105:1072-79.
  3. Berntorp E and Windyga J. Haemophilia 2009; 15:122-30.
  4. Nowak-Göttl U et al. Haemophilia 2013; 19:887-92.
  5. Batty P et al. Haemophilia 2014; 20: 846-53.
  6. Khair K et al. Haemophilia 2015; 21:e44-50.
  7. Sholzberg M et al. TH Open 2021; 5:e264-72.